NYSE · JNJ

Johnson & Johnson

$263.40 +$4.13 (+1.59%) 1D After hours
Session Pulse Overnight session 4 mentions on Fri · 3 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →
Charting by TradingView

Key Metrics

$624.12B
Market cap
29.66×
P/E · TTM
$96.36B
Revenue · TTM
$21.04B
Net income
EPS · TTM $8.68
Dividend yield —
Free cash flow $17.78B
Beta · 1Y -0.16
EBITDA · TTM $32.68B
Gross margin 67.8%

Snapshot

Market cap$624.12B
Enterprise value$639.60B
Shares outstanding2.4B
52-wk range$164.23 – $269.43
Avg volume · 20D8.3M
Net cash −$15.48B
Book value / share$33.50
IndustryPharmaceutical Preparations
ExchangeNYSE
About Johnson & Johnson
IPO dateSep 25, 1944
Employees140800

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E29.66
P/S6.48
P/FCF35.09
EV/EBITDA19.57
EV/Sales6.64
Graham №$80.88

Profitability

Gross 67.8%
Operating 25.9%
Net 21.8%
FCF 18.5%
ROE / ROIC 27.6% · 21.8%

Financial Health

Current ratio1.03
Quick ratio0.77
Debt / equity0.46
Debt / EBITDA 1.15
Net cash −$15.48B
Working capital$1.46B

Cash Flow · TTM

Operating CF $22.87B
Capex −$5.09B
Free cash flow $17.78B
Buybacks $7.85B
Dividends paid —
Shareholder yield 1.3%

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

5.2
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$80.88 vs $263.40
Trades 3.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-29 · computed by TickerWolf from SEC filings